financetom
Business
financetom
/
Business
/
Italy's Intesa partners with BlackRock in private banking in Benelux
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Italy's Intesa partners with BlackRock in private banking in Benelux
Nov 11, 2024 6:18 AM

MILAN (Reuters) - Italy's largest bank Intesa Sanpaolo said it would partner with BlackRock ( BLK ), the world's biggest asset manager and a leading Intesa shareholder, to offer digital wealth management services to clients in Belgium and Luxembourg.

By teaming up with BlackRock ( BLK ), Intesa Sanpaolo's private banking unit Fideuram will broaden its digital offering of investments to clients in those two countries, with a view to expanding further in Europe.

"This agreement is a perfect fit with our strategy based on the growth of our wealth management business and the development of new digital solutions," CEO Carlo Messina said.

With a strong focus on its home country, which accounts for the bulk of its profits, Intesa has bet on investments in technology to grow.

It launched last year Fideuram Direct, a digital private banking channel to serve younger customers leveraging technology to compete in a sector where players are increasingly betting on scale to lower costs.

Messina has repeatedly said there are no wealth management targets Intesa could buy at prices that would deliver value for shareholders.

Intesa can't expand domestically due to antitrust limits after buying smaller peer UBI in 2020. A cross-border deal like the possible Commerzbank buy being explored by crosstown rival UniCredit would not provide enough cost cuts without the foreign presence of UniCredit, Messina has said.

Earlier this year Intesa reorganised its core wealth management activities under veteran executive Tommaso Corcos, widely seen as one of the potential successors to CEO Messina in the future.

On Friday, Intesa said it was further simplifying its wealth management divisions.

It said it would have one division within its Eurizon asset management business in charge of funds, and another division within Fideuram in charge of all portfolio management services offered by financial advisors and private bankers.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: Chevron Cabinda Gulf Operations Resume After Release of Oil
Update: Chevron Cabinda Gulf Operations Resume After Release of Oil
Jan 28, 2025
04:58 AM EST, 01/28/2025 (MT Newswires) -- (Updates with attribution to Chevron ( CVX ) throughout and additional information in the last two paragraphs.) Chevron ( CVX ) said its Cabinda Gulf Oil operations in Angola have resumed normal operations after an oil sheen and debris were found nearby along the Atlantic Ocean coastline. About five barrels of oil were...
Fundstrat's Tom Lee Sees Nvidia's 17% Plunge As An 'Opportunity,' Calls Nasdaq's Over 600 Points Plunge Drop A Market 'Overreaction'
Fundstrat's Tom Lee Sees Nvidia's 17% Plunge As An 'Opportunity,' Calls Nasdaq's Over 600 Points Plunge Drop A Market 'Overreaction'
Jan 28, 2025
Fundstrat Global Advisors‘ head of research Tom Lee believes Monday’s massive tech sector sell-off, which saw Nvidia Corp. ( NVDA ) shares plunge 17%, represents a buying opportunity rather than a fundamental shift in the artificial intelligence landscape. What Happened: “To me, it’s an overreaction,” Lee told CNBC’s “Closing Bell,” comparing the drop to Nvidia’s March 2020 decline that proved...
Drugs Made In America Acquisition Prices $200 Million IPO
Drugs Made In America Acquisition Prices $200 Million IPO
Jan 28, 2025
04:49 AM EST, 01/28/2025 (MT Newswires) -- Drugs Made In America Acquisition (DMAA) said late Monday it priced an initial public offering of 20 million units at $10 each. The company granted the underwriter a 45-day option to purchase up to an additional 3 million units. Each unit consists of one ordinary share and one right to receive one-eighth of...
AstraZeneca, Daiichi Sankyo's Enhertu Gets US FDA Approval for Treatment of Inoperable Breast Cancers
AstraZeneca, Daiichi Sankyo's Enhertu Gets US FDA Approval for Treatment of Inoperable Breast Cancers
Jan 28, 2025
04:57 AM EST, 01/28/2025 (MT Newswires) -- AstraZeneca ( AZN ) and Daiichi Sankyo said their drug Enhertu has been approved in the US for the treatment of adult patients with certain types of inoperable breast cancer that has progressed on one or more endocrine therapies. The drug, also known as fam-trastuzumab deruxtecan-nxki, has specifically been approved for use in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved